Ann: Phase 2a Trial Result Release Interview Video Recording, page-4

Just watched the video with DP & KH.

I've gotta say, that was perhaps more elucidating than anything put out by the company to date. Whether it's the medical person talking (might be?) I don't know...

So, there were no FSGS patients in the study? Hmmm....I'm hypothesisng again, especially given he stressed about diabetes and the interstitial inflammation, but I'm thinking you'll find that the best responders were the diabetics.
They're easy to find for studies, cos there's plenty of 'em.
And 48% of them saw benefit enough to continue the therapy! You'd say that would be those seeing a >30% reduction, as those were the figures he mentioned.

Refer to my post last night in the conference call thread, outlining the pathophysiologic reasons for this hypothesis.

I think the Ph2B will be predominately diabetics with FSGS patients included.